Clinical trials

The current consensus is that, right now, there isn’t a large enough body of evidence to prove that cannabis (or any of its active compounds or derivatives) can reliably treat any form of cancer but the medical use of cannabis to treat cancer-related chronic pain is approved in the UK.

Sacituzumab govitecan (Trodelvy) is not being recommended by NICE for use in England as a treatment for some people with triple-negative breast cancer.

A study by Oxford University has found that aromatase inhibitors are better than tamoxifen at reducing the risk of breast cancer recurrence in both younger and older women.

To mark 20 years since the merger of the Cancer Research Campaign and the Imperial Cancer Research Fund, we’ve delved into the research of the charities’ that led to many of the drugs in use today.

Professor Eithne Costello on the challenges of ambitious trials, the evolution of early detection as a field in its own right and why a guiding framework is all important.

Pioneering therapeutics targeting the damage repair mechanism of DNA polymerase theta in a range of cancers have entered human trials – we tell the story from discovery to translation.

We hear from Rosie Lomas – the ‘Excellence in Cancer Research Nursing Award’ winner – and the other shortlisted nurses about their work and the vital role they play in delivering clinical trials.

Patients taking the drug trastuzumab deruxecan were 72% less likely to see their cancer grow significantly or to die than those on an existing breast cancer treatment.

Find out how the chemistry inside plants can lead to life-changing drugs and how a cannabis-derived drug is part of a new trial to help people with a type of aggressive brain cancer.

The charity’s commercial arm saw the amount of money from both internal and external sources invested in its spinouts more than double in the last year.